(vianews) - shares of genfit (cac 40: gnft.pa) dropped 9.09% to €3.80 at 11:52 est on thursday, following the last session's upward trend. cac 40 is falling 1.21% to €7,172.96, after three sequential sessions in a row of losses. this seems, as yet, an all-around bearish trend trading session today.
about genfit
genfit s.a., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. the company develops elafibranor, which is in phase iii clinical trial to treat patients with primary biliary cholangitis. it also engages in the development of nis4 technology for the diagnosis of nonalcoholic steatohepatitis (nash) and fibrosis; vs-01 for the treatment of urea cycle disorder (ucd) and organic acidemia disorder (oad); gns561, which is in phase 1b/2 trial to treat patients with cholangiocarcinoma (cca); and vs-01-aclf and nitazoxanide (ntz), which is in phase 1 trial to treat acute-on-chronic liver failure, as well as vs-02-he, which is in preclinical trial for the treatment of reduction of hyperammonemia and the stabilization of blood ammonia. the company has a licensing agreement with labcorp for the commercialization of nashnext, a blood-based molecular diagnostic test; and genoscience pharma to develop and commercialize the investigational treatment gns561 for cca. the company was incorporated in 1999 and is headquartered in loos, france.
earnings per share
as for profitability, genfit has a trailing twelve months eps of €-0.48.
volume
today's last reported volume for genfit is 273604 which is 171.72% above its average volume of 100692.
more news about genfit (gnft.pa).